IFN-beta Protein, Human, Recombinant

IFN-beta Protein, Human, Recombinant: 製品情報

純度
> 95 % as determined by SDS-PAGE
内毒素
< 1.0 EU per μg of the protein as determined by the LAL method
活性
Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.
タンパク質の構築
A DNA sequence encoding the human IFNβ (P01574) (Met1-Asn187) was expressed.
Uniprot No.
発現ホスト
CHO Stable Cells
Human
予測N末端
Met 22
分子量
The recombinant human IFNβ consists of 166 amino acids and predicts a molecular mass of 20 KDa. It migrates as an approximately 20-23 KDa band in SDS-PAGE under reducing conditions.
バッファー
Lyophilized from sterile 10mM NaAC, 40mM Arg, 0.12mg/ml Met, 146mg/ml Sucrose, 0.1% PF-68, pH 4.5
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
配送
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
安定性 & 保存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
再構成
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

IFN-beta Protein, Human, Recombinant: 画像

Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.

IFN-beta Protein, Human, Recombinant: 別名

IFB Protein, Human; IFF Protein, Human; IFN-beta Protein, Human; IFNB Protein, Human; Interferon beta Protein, Human

IFN-beta 背景情報

Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.
完全な名称
interferon, beta 1, fibroblast
参考文献
  • Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
  • Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
  • Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.
  • A potent in vivo anti-tumor efficacy of novel recombinant type I interferon
    Author
    Zhang, K;Yin, XF;Yang, YQ;Li, HL;Xu, YN;Chen, LY;Liu, XJ;Yuan, SJ;Fang, XL;Xiao, J;Wu, S;Xu, H;Chu, L;Katlinski, KV;Katlinskaya, YV;Guo, RB;Wei, GW;Wang, DC;Liu, X;Fuchs, SY;
    Year
    2016
    Journal
    Clin. Cancer Res.
    Application
    binding
  • A potent in vivo anti-tumor efficacy of novel recombinant type I interferon
    Author
    Zhang, K;Yin, XF;Yang, YQ;Li, HL;Xu, YN;Chen, LY;Liu, XJ;Yuan, SJ;Fang, XL;Xiao, J;Wu, S;Xu, H;Chu, L;Katlinski, KV;Katlinskaya, YV;Guo, RB;Wei, GW;Wang, DC;Liu, X;Fuchs, SY;
    Year
    2016
    Journal
    Clin. Cancer Res.
    Application
    binding
  • Human Virus-Derived Small RNAs Can Confer Antiviral Immunity in Mammals
    Author
    Qiu, Y;Xu, Y;Zhang, Y;Zhou, H;Deng, YQ;Li, XF;Miao, M;Zhang, Q;Zhong, B;Hu, Y;Zhang, FC;Wu, L;Qin, CF;Zhou, X;
    Year
    2017
    Journal
    Immunity
    Application
    cell-based
  • Influenza Virus NS1 Protein RNA-Interactome Reveals Intron Targeting
    Author
    Zhang, L;Wang, J;Muñoz-Moreno, R;Kim, M;Sakthivel, R;Mo, W;Shao, D;Anantharaman, A;García-Sastre, A;Conrad, NK;Fontoura, BMA;
    Year
    2018
    Journal
    J. Virol.
    Application
    cell-based
  • FAF1 Regulates Antiviral Immunity by Inhibiting MAVS but Is Antagonized by Phosphorylation upon Viral Infection
    Author
    Dai, T;Wu, L;Wang, S;Wang, J;Xie, F;Zhang, Z;Fang, X;Li, J;Fang, P;Li, F;Jin, K;Dai, J;Yang, B;Zhou, F;van Dam, H;Cai, D;Huang, H;Zhang, L;
    Year
    2018
    Journal
    Cell Host Microbe
    Application
    cell-based
カートに追加しました カートに追加しませんでした カートを更新しています。少々お待ちください U.S.A.